Clinical trials: Niraparib
Lung Small Cell Carcinoma, Neuroendocrine Carcinoma
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
This phase II trial studies the effect of niraparib and dostarlimab in treating small cell lung cancer and other high-grade neuroendocrine carcinomas.
- Conditions
- Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT04701307
- Testing
- Dostarlimab, Niraparib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma,Soft Tissue, Sarcoma Uterus
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
The purpose of this study is to test whether the study drug, niraparib, is effective against unresectable and/or metastatic soft tissue sarcoma with DDR mutations.
- Trial name
- NCT05515575
- Testing
- Niraparib
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer, Triple Negative Breast Cancer
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or…
- Conditions
- Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma
- Trial name
- NCT04178460
- Testing
- Niraparib combined with MGD013
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Ovarian Carcinoma
Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency
Background: High-grade serous epithelial ovarian cancer is a disease with a poor prognosis in the advanced stages (stages III and IV).
- Trial name
- OVNI-B (NCT06827353)
- Testing
- maintenance therapy with bevacizumab, maintenance therapy with niraparib
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Ovarian Cancer, Fallopian Tube Cancer
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, and primary peritoneal cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Cancer Stage III
- Trial name
- NCT04701645
- Testing
- Microdevice
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Ovarian Neoplasm
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal…
- Trial name
- COHORT-A (NCT05751629)
- Testing
- Dostarlimab, Bevacizumab, Niraparib
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Tesaro, Inc.
Pancreatic Cancer
Niraparib in Patients With Pancreatic Cancer
This research study is studying an investigational therapy as a possible treatment for pancreatic cancer. The drugs involved in this study are: -Niraparib
- Trial name
- NCT03601923
- Testing
- Niraparib
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
The purpose of this study is to assess the safety and pharmacokinetics of niraparib when administered in combination with an androgen receptor (AR)-targeted therapy (apalutamide or abiraterone acetate plus prednisone) in adult…
- Trial name
- NCT02924766
- Testing
- Niraparib, Apalutamide, Abiraterone Acetate
- Where
- 6 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Janssen Research & Development, LLC
SCLC,Extensive Stage, SLFN11-positive
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance.
- Trial name
- RAISE (NCT05718323)
- Testing
- Niraparib
- Where
- 18 sites in France, Germany and 3 more
- Volunteers
- 44 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer
Randomized phase II trial targeting early-stage breast cancer (stage II-III) applicable to preoperative chemotherapy (NAC), comparing standard treatment with multiple experimental treatments.
- Trial name
- NCT06535893
- Testing
- TN, TN-1
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Nagoya City University
Metastatic Prostate Cancer
Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
This is a phase I study to determine the safety and feasibility of the combination of enzalutamide and niraparib in subjects with metastatic castration-resistant prostate cancer (CRPC).
- Trial name
- NCT02500901
- Testing
- Enzalutamide, Niraparib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Paul Mathew, MD
Advanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with elimusertib in combination with niraparib.
- Trial name
- NCT04267939
- Testing
- Elimusertib (BAY1895344), Niraparib
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Bayer
Metastatic Castration-resistant Prostate Cancer
Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)
The purpose of this pre-approval access is to provide Niraparib plus Abiraterone Acetate (Nira/AA combination) in the treatment of (a) participant(s) with first line metastatic castration-resistant prostate cancer with specific…
- Trial name
- NCT05401214
- Testing
- Niraparib plus Abiraterone Acetate (Nira/AA) combination, Prednisone/Prednisolone
- Sponsor
- Janssen Research & Development, LLC
Ovarian Cancer
Efficacy and Adverse Effects of Niraparib in Ovarian Cancer.
Ovarian cancer is the second fatal gynecological cancer. More than 70% of ovarian cancer patients are diagnosed as advanced. Niraparib was approved by the National Medical Products Administration on December 27, 2019.
- Trial name
- NCT05583799
- Volunteers
- 222 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Breast Cancer, Ovarian Cancer
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
Open-label, cohort study to determine the feasibility and tolerability of the combination of daily niraparib and daily or thrice weekly everolimus for one 28-day cycle in patients with advanced ovarian and breast cancer.
- Trial name
- NCT03154281
- Testing
- niraparib, everolimus
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Castration-Resistant Prostatic Cancer
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
- Trial name
- MAGNITUDE (NCT03748641)
- Testing
- Niraparib, Abiraterone Acetate, Prednisone
- Where
- 318 sites in United States, Argentina and 27 more
- Volunteers
- 765 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
SMMART Adaptive Clinical Treatment (ACT) Trial
SMMART-ACT is a feasibility pilot study to determine if testing samples from a participant's cancer using a precision medicine approach can be used to identify specific drugs or drug combinations that can help control their…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma
- Trial name
- NCT05238831
- Testing
- Alectinib, Alpelisib, Anastrozole
- Sponsor
- OHSU Knight Cancer Institute
Stage I Breast Cancer, Stage II Breast Cancer
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations.
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer
- Trial name
- NCT04584255
- Testing
- Niraparib, Dostarlimab
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Dana-Farber Cancer Institute
Endometrial Carcinoma, P53 Mutation
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
This is an umbrella, two-arm, multi-stage, phase II trial. The purpose of the trial in the early stage cohort is to determine if EBRT improves disease free survival (defined as the time from random assignment to disease…
- Conditions
- Endometrial Carcinoma, P53 Mutation, Serous Carcinoma
- Trial name
- CAN-STAMP (NCT04159155)
- Testing
- External Beam Radiation, Niraparib, Vaginal high-dose rate brachytherapy
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University Health Network, Toronto
Extensive-stage Small Cell Lung Cancer
A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Niraparib is a PARP inhibitor. The study is a 2:1 randomized, double-blind, placebo-controlled, multi-center,phase 3 study of ZL-2306 (niraparib) as maintenance therapy following first-line platinum-based chemotherapy in patients…
- Trial name
- NCT03516084
- Testing
- ZL-2306(nirapairb)
- Where
- 33 sites in China
- Volunteers
- 185 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.